Healthcare Global Respiratory Inhalers Market | Page 3

REPORT DESCRIPTION
Global Respiratory Inhalers Market – Taxonomy
●
●
●
In September, GlaxoSmithKline plc, received approval for Trelegy Ellipta. Trelegy Ellipta, is the first
once-daily use inhaler triple therapy (i.e. combination of 3 active molecules in a single inhaler) for the
treatment of Chronic Obstructive Pulmonary Disease (COPD).
In April, 2016, AstraZeneca received approval for Bevespi Aerosphere, the first product which uses
AstraZeneca’s Co-Suspension Technology. The technology enables more than one medicine delivery
from a single MDI.
In 2010, around 115,000 patients were hospitalized due to sever chronic obstructive pulmonary disease,
which cost the NHS around US$ 367.85 Mn and is expected to increase over the forecast period. Sandoz
launched an innovative respiratory inhaler AirFluSal Forspiro in the UK in 2015, to capitalize on the
highly lucrative market in the region.
Get PDF Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/227